Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Histiocyte/Dendritic Cell Neoplasms and Relapsed/Refractory Aggressive Lymphomas
NCT03316573Phase 2Suspended
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2017
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in lymphoma, histiocytic sarcoma (HS), Follicular Dendritic Cell Sarcoma (FDCS), Interdigitating dendritic cell sarcoma (IDCS), sponsored by Dana-Farber Cancer Institute. Started Dec 2017; status: suspended.
02
Drugs
03
Conditions
lymphomahistiocytic sarcoma (HS)Follicular Dendritic Cell Sarcoma (FDCS)Interdigitating dendritic cell sarcoma (IDCS)
Beyond the preview
Go deeper on NCT03316573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316573.